Delivery Order SPE2DB22D7065-SPE2DB25FH3LU
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $7,764.93 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) with a completion date of August 20, 2025. This competitive award, issued on August 19, 2025, carries firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The place of performance is AmerisourceBergen's corporate office location...
- The Defense Logistics Agency awarded a delivery order valued at $12,445.76 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Otezla 30 mg tablets (60-count units) under a firm fixed-price contract with a ceiling value of $1,311.62. This non-set-aside award represents a competitive procurement action and demonstrates continued federal utilization of AmerisourceBergen's pharmaceutical distribution capabilities for military healthcare needs. The place of performance is AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a $31,530.56 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Otezla 30 mg tablets (60-count packages). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 28, 2025. The delivery order is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and primary...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor based in Conshohocken, Pennsylvania, received a firm fixed price delivery order from the Defense Logistics Agency's Medical Supply Chain for Otezla 30 mg tablets (60-count units) valued at $35,634.81. This non-set-aside, competitively awarded contract was issued on August 7, 2025, with an ultimate completion date of August 8, 2025. The order represents a standard pharmaceutical supply delivery executed under AmerisourceBergen's...
- AmerisourceBergen Drug Corp received a delivery order from the Defense Logistics Agency (DLA) on August 19, 2025, for the supply of Otezla 30 mg tablets (60-count units) valued at $34,867.15. The contract, which is not designated as a set-aside, carries a firm fixed price structure with an ultimate completion date of August 20, 2025. This delivery order serves as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency awarded a delivery order valued at $11,258.73 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count packages). This firm fixed price contract, awarded on August 19, 2025, with completion expected by August 20, 2025, carries no set-aside designation and was competitively awarded. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a routine...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Otezla 30 mg tablets (60-count packaging) with a ceiling value of $27,320.78. This firm fixed-price delivery order, which is expected to be completed by July 24, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was made through open competition with no set-aside designation, reflecting...
- The Defense Logistics Agency awarded a $13,321.78 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Otezla 30 mg tablets (60-count packages) on July 24, 2025, with an ultimate completion date of July 25, 2025. This is a non-set-aside competitive award issued as a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.999 billion through December 2026. The pharmaceutical distributor, headquartered in...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order valued at $33,358.49 by the Defense Logistics Agency (DLA) for the supply of Otezla 30 mg tablets in quantities of 60. The contract is structured as a firm fixed price delivery order with a completion date of September 2, 2025, and was competitively awarded without set-aside provisions on August 29, 2025. Performance will be executed at the company's corporate office location in...
- SPE2DB22D7065Indefinite Delivery Contract
- SPE2DB22D7065-SPE2DB25FH3LUDelivery Order
AmerisourceBergen Drug Corp was awarded a delivery order on August 29, 2025, valued at $2,623.24 for the supply of Otezla 30 mg tablets (60-count units) to the Defense Logistics Agency. The contract utilizes a firm fixed price model with no set-aside designation, indicating competitive award status. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 2, 2025. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026 that enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to military healthcare programs worldwide. The Defense Logistics Agency Medical Supply Chain relies on AmerisourceBergen's expansive pharmaceutical distribution network to support military and veteran healthcare systems. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen maintains an extensive portfolio of brand-name and generic medications across multiple therapeutic domains through its federal contracting relationships. This particular delivery order for Otezla, a branded pharmaceutical treatment, reflects the ongoing need for specialized medical commodities within the Defense Health Agency and broader military medical supply infrastructure. The award demonstrates AmerisourceBergen's continued capability to fulfill federal medical procurement requirements through open competition and its role as a critical vendor in the federal pharmaceutical distribution ecosystem.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.6k | 8/29/25 |